Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Sevoflurane Sedation in ICU Patients at Risk of ARDS
2024-517670-15-00Phase 3Completed
- Sponsor
- CHU Gabriel-Montpied
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sevoflurane in acute respiratory distress syndrome (ARDS), pneumonia, multiple organ dysfunction syndrome (MODS) and 1 more (2 arms), sponsored by CHU Gabriel-Montpied. Primary endpoint: Longitudinal evolution in the PaO2/FiO2 ratio. Started Oct 2024; status: completed.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)pneumoniamultiple organ dysfunction syndrome (MODS)delirium
Beyond the preview
Go deeper on 2024-517670-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517670-15-00.